Enterprise Value
-2.858M
Cash
3.096M
Avg Qtr Burn
-16.08M
Short % of Float
3.75%
Insider Ownership
10.35%
Institutional Own.
4.34%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lenzilumab Details Graft-versus-host disease | Phase 2/3 Data readout | |
Lenzilumab Details Leukemia, Chronic myelomonocytic leukemia | Phase 2/3 Interim update | |
Ifabotuzumab (iFab) Details Glioblastoma, Cancer | Phase 1b Initiation | |
Lenzilumab Details COVID-19 | Failed Discontinued | |
Lenzilumab Details Cancer, Non-Hodgkin lymphoma | Failed Discontinued | |
Lenzilumab with CAR-T Details B-cell malignancies, Cancer | Failed Discontinued | |
Lenzilumab Details Respiratory conditions, Asthma | Failed Discontinued |